Incidence and prevalence of Neurofibromatosis type 1 and 2: a systematic review and meta-analysis [PDF]
, 2023 Tin‐Suet Joan Lee +4 more
openalex +1 more source
Current progress in genomics and targeted therapies for neurofibromatosis type 2. [PDF]
Fukushima J Med Sci, 2023 Hiruta R, Saito K, Bakhit M, Fujii M.
europepmc +1 more source
Data from Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2
, 2023 Karo Tanaka +12 more
openalex +1 more source
Co‐occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2 [PDF]
, 2020 R. Peces +9 more
openalex +1 more source
Reduction of sporadic and neurofibromatosis type 2–associated vestibular schwannoma growth in vitro and in vivo after treatment with the c-Jun N-terminal kinase inhibitor AS602801 [PDF]
, 2022 Mark C. Dougherty +5 more
openalex +1 more source
Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma. [PDF]
Mol Ther Methods Clin Dev, 2023 Blackwood N, Zetzmann C, Trevino CR.
europepmc +1 more source
Two Cases of Spinal Tanycytic Ependymoma Associated with Neurofibromatosis Type 2
, 2017 Xiaogang Tao +4 more
openalex +1 more source
Neurofibromatosis Type-2 presenting with vision impairment. [PDF]
Pak J Med Sci, 2023 Alshoabi SA.
europepmc +1 more source